Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$120.49
+0.2%
$116.23
$75.40
$125.14
$297.59B0.1810.76 million shs1.53 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$50.81
-0.4%
$56.07
$29.08
$65.00
$7.35B1.31.41 million shs180,943 shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.14
-0.3%
$26.82
$23.06
$28.75
$149.01B0.3541.32 million shs5.62 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.43%+6.42%+9.06%+0.81%+55.18%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+1.82%+8.16%-14.57%-14.97%+60.79%
Pfizer Inc. stock logo
PFE
Pfizer
+1.47%+1.80%-2.14%-3.21%+11.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$120.49
+0.2%
$116.23
$75.40
$125.14
$297.59B0.1810.76 million shs1.53 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$50.81
-0.4%
$56.07
$29.08
$65.00
$7.35B1.31.41 million shs180,943 shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.14
-0.3%
$26.82
$23.06
$28.75
$149.01B0.3541.32 million shs5.62 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.43%+6.42%+9.06%+0.81%+55.18%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+1.82%+8.16%-14.57%-14.97%+60.79%
Pfizer Inc. stock logo
PFE
Pfizer
+1.47%+1.80%-2.14%-3.21%+11.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$128.186.38% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.63
Moderate Buy$86.0069.27% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.619.47% Upside

Current Analyst Ratings Breakdown

Latest PCVX, PFE, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingNeutral$27.00
5/15/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DowngradeHold (C+)Hold (C)
5/14/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$26.00
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/6/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageNeutral$125.00
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Reiterated RatingHold (C+)
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Lower Price TargetOverweight$150.00 ➝ $145.00
4/29/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetNeutral$26.00 ➝ $27.00
4/20/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingUnderperform$25.00
4/16/2026
Pfizer Inc. stock logo
PFE
Pfizer
Initiated CoverageOutperform$33.00
4/13/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$130.00 ➝ $145.00
(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.58$11.50 per share10.48$18.60 per share6.48
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$20.75 per shareN/A
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.38$4.44 per share5.88$15.86 per share1.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5533.9412.322.6913.59%27.55%10.73%8/4/2026 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.969.14N/A11.83%19.44%8.41%8/4/2026 (Estimated)

Latest PCVX, PFE, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.82%+5.75%95.77%14 Years
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.58%-13.20%131.30%16 Years

Latest PCVX, PFE, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/26/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.84%6/15/20266/15/20267/8/2026
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
7.49
7.49
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160144.40 million139.92 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Mailbag: A Follow-Up on Pfizer and Other Questions
Pfizer (NYSE:PFE) Shares Up 1.5% - Should You Buy?
3 Dividend Stocks Yielding Above 5% to Scoop Up Now
Thinning revenues: inside the $14bn Eliquis patent cliff
If Viking Therapeutics Is Acquired, Here's Who Wins
Arnhold LLC Raises Stock Holdings in Pfizer Inc. $PFE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$120.49 +0.25 (+0.20%)
As of 11:17 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$50.80 -0.22 (-0.42%)
As of 11:17 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Pfizer stock logo

Pfizer NYSE:PFE

$26.14 -0.08 (-0.29%)
As of 11:17 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.